In a news release on Monday, Moderna Inc. (MRNA) announced that Dr. Paul Burton would be taking over as head of the medical department as of July 6. Burton currently holds the position of head of medical affairs for Johnson & Johnson.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
It was announced earlier this year that Dr. ZalTaks would be leaving the company. Burton will cover for him. Dr. Burton will be a member of the American biotechnology company’s executive committee and directly report to the CEO of Moderna, Stephan Bancel, alongside the other members of the executive committee. StéphaneBancel said in a statement, “Paul’s extensive medical experience for the global pharmaceutical and biotechnology industry will greatly assist Moderna as it expands internationally and continues its journey as a trading company.”
The experience Paul brings in several therapeutic areas, and his proven track record of successfully utilizing data science and digital technologies for transformational medicine will be an asset in the effort to create a new generation of medicines for patients based on mRNA technology. The CEO of Moderna said he was eager to work with Paul.
Dr. Burton worked at Johnson & Johnson for 16 years before joining Moderna Inc. (MRNA). He has been assigned as Managing Director of Medical Affairs at Janssen Pharmaceuticals since March 2020. In this role, he oversees medical affairs strategies and execution globally.
Moderna Inc. (MRNA) shares closed yesterday’s trading session at $207.41, a -5.23% down. As of the close of the last trading session, MRNA stock was trading at $218.85. During the last trading session, MRNA’s stock price fluctuated between $198.00 and $213.4899. The number of shares exchanged was 11.74 million, greater than the company’s 50-day daily volume of 9.87 million and higher than its Year to date volume of 11.14 million. Over the past 12 months, the company’s stock has advanced 234.53%, and in the last week, the stock has fallen -5.54%. Its shares have risen by 33.22% in the past six months and 44.38% in the past three months. So far this year, the stock has returned 98.54%. Additionally, the stock is trading at a price-to-earnings ratio of 165.40.
